Technical Analysis for CLVSQ - Clovis Oncology Inc

Grade Last Price % Change Price Change
D 0.1100 -8.33% -0.0100
CLVSQ closed down 8.33 percent on Friday, February 3, 2023, on 23 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Shooting Star Candlestick Bearish -8.33%
Narrow Range Bar Range Contraction -8.33%
Doji - Bearish? Reversal -8.33%
NR7 Range Contraction -8.33%
NR7-2 Range Contraction -8.33%
Narrow Range Bar Range Contraction -8.33%
Inside Day Range Contraction -8.33%
NR7 Range Contraction -10.93%
Narrow Range Bar Range Contraction -10.93%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% 20 days ago
Down 5% 20 days ago
Down 3% 20 days ago
Down 1% 20 days ago
Down 2% 20 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Clovis Oncology Inc Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Imaging Organic Compounds U.S. Bankruptcy Court Chemical Compounds Alpha Oncology U.S. Bankruptcy Court For The District Of Delaware Ovarian Cancer Lactams Metastatic Castration Resistant Prostate Cancer Parp Inhibitors

Is CLVSQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 0.19
52 Week Low 0.05
Average Volume 1,187,825
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.1163
Average True Range 0.0292
RSI 57.26
ADX 0.0
+DI 27.0660
-DI 19.1443
Chandelier Exit (Long, 3 ATRs) 0.1024
Chandelier Exit (Short, 3 ATRs) 0.1376
Upper Bollinger Bands 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line -0.0046
MACD Signal Line -0.0029
MACD Histogram -0.0017
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1250
Resistance 3 (R3) 0.1267 0.1233 0.1225
Resistance 2 (R2) 0.1233 0.1195 0.1225 0.1217
Resistance 1 (R1) 0.1167 0.1172 0.1150 0.1150 0.1208
Pivot Point 0.1133 0.1133 0.1125 0.1125 0.1133
Support 1 (S1) 0.1067 0.1095 0.1050 0.1050 0.0992
Support 2 (S2) 0.1033 0.1072 0.1025 0.0983
Support 3 (S3) 0.0967 0.1033 0.0975
Support 4 (S4) 0.0950